

**Supplementary Table 1. Demographic and clinical characteristics of the patients with autoimmune diseases other than systemic lupus erythematosus**

Disease	Systemic sclerosis (n = 1,157)	RA (n = 21,895)	DM/PM (n = 1,237)	Pemphigus (n = 856)	Sjogren's syn- drome (n = 14,470)	IBD (n = 1,883)
Sex, male/female	317/840	5,260/16,635	427/810	402/454	1,475/12,995	1,177/706
Age at onset of autoimmune disease, yr	53.3 ± 14.2	54.2 ± 14.2	51.4 ± 14.5	53.9 ± 16.3	54.9 ± 14.1	44.2 ± 15.0
AVN	6 (0.5)	186 (0.8)	26 (2.1)	20 (2.3)	53 (0.4)	11 (0.6)
<b>Comorbidities</b>						
Diabetes mellitus	112 (9.7)	2,295 (10.5)	172 (13.9)	121 (14.1)	1,022 (7.1)	105 (5.6)
Hypertension	290 (25.1)	5,200 (23.7)	279 (22.6)	180 (21.0)	2,560 (17.7)	180 (9.6)
Hyperlipidemia	97 (8.4)	1,860 (8.5)	102 (8.2)	68 (7.9)	1,122 (7.8)	64 (3.4)
Gout	34 (2.9)	1,028 (4.7)	32 (2.6)	10 (1.2)	282 (1.9)	31 (1.6)
Asthma	46 (4.0)	805 (3.7)	47 (3.8)	18 (2.1)	501 (3.5)	17 (0.9)
COPD	34 (2.9)	448 (2.0)	43 (3.5)	17 (2.0)	224 (1.5)	10 (0.5)
Proteinuria	6 (0.5)	80 (0.4)	5 (0.4)	4 (0.5)	84 (0.6)	1 (0.1)
Nephrotic syndrome	13 (1.1)	58 (0.3)	2 (0.2)	2 (0.2)	44 (0.3)	1 (0.1)
End-stage renal disease	21 (1.8)	73 (0.3)	7 (0.6)	5 (0.6)	45 (0.3)	3 (0.2)
Mean daily dose of prednisone-equivalent dose, mg/day	3.8 ± 8.4	2.6 ± 3.6	11.6 ± 20.8	7.7 ± 9.0	1.3 ± 3.8	2.1 ± 4.3
Low dose, ≤ 7.5	1,002 (86.6)	20,411 (93.2)	664 (53.7)	540 (63.1)	13,981 (96.6)	1,742 (92.5)
Medium dose, 7.51–30	141 (12.2)	1,456 (6.6)	488 (39.5)	290 (33.9)	452 (3.1)	134 (7.1)
High dose, > 30	14 (1.2)	28 (0.1)	85 (6.9)	26 (3.0)	37 (0.3)	7 (0.4)
Total cumulative dose of corticosteroid, g	3.6 ± 5.1	3.6 ± 4.8	9.6 ± 11.2	9.2 ± 12.0	1.4 ± 3.6	2.5 ± 5.3

Values are presented as mean ± standard deviation or number (%).

RA, rheumatoid arthritis; DM, dermatomyositis; PM, polymyositis; IBD, inflammatory bowel disease; AVN, avascular necrosis; COPD, chronic obstructive pulmonary disease.